Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage.
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Contusugene ladenovec (Primary) ; Antineoplastics
- Indications Head and neck cancer
- Focus Therapeutic Use
- Sponsors Shenzhen SiBiono GeneTech
- 10 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 14 May 2009 New trial record